Literature DB >> 7262171

Serum and saliva levels of a trimethoprim-sulfamethopyrazine combination in man.

A Sardi, M P Vettaro, R Alesina, S Grasso, G Meinardi, I de Carneri, V Tamassia.   

Abstract

A combination of trimethoprim (TMP) and sulfamethopyrazine (SMP) was administered to six healthy volunteers for 8 days, according to the proposed therapeutic repeated dose schedule. The weak base TMP (pKa = 7.3) and the weak acid SMP (pKa = 6.1) were measured simultaneously in serum and saliva, both under normal conditions and after stimulation of saliva flow. The flow of saliva was stimulated by chewing plastic material in order to obtain saliva at a pH close to the normal plasma pH of 7.4. This procedure excluded pH-dependent distribution effects. Under these experimental conditions a highly significant correlation was observed between the serum and saliva concentrations of both drugs, with very small inter- and intraindividual variations. Substantial agreement was found between the saliva:serum concentration ratio and the fractions of both drugs not bound to plasma protein. Some discrepancies were noted, probably due to minor shifts in saliva pH during the collection period.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7262171     DOI: 10.1007/BF00607146

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Relationship between digoxin concentrations in serum and saliva.

Authors:  D H Huffman
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

2.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

Authors:  E S Vesell; G T Passananti; P A Glenwright; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

3.  The permeability of the human parotid gland to a series of sulfonamide compounds, para-aminohippurate and inulin.

Authors:  S A KILLMANN; J H THAYSEN
Journal:  Scand J Clin Lab Invest       Date:  1955       Impact factor: 1.713

4.  Drug concentration in saliva.

Authors:  J C Mucklow; M R Bending; G C Kahn; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

5.  [Salivary excretion of sulphonamides. Correlation of drug levels in saliva and ultrafiltrate of plasma (author's transl)].

Authors:  A Grüneisen; H Witzgall
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

7.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

8.  Salivary excretion of paracetamol in man.

Authors:  J P Glynn; W Bastain
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

9.  Pharmacokinetic study of a sulfametopyrazine/trimethoprim combination (Kelfiprim) in human volunteers.

Authors:  D S Reeves; M J Bywater; D W Bullock; H A Holt
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

10.  Quantitative determination of the bacteriostatically active fraction of sulfonamides and the sum of their inactive metabolites in the body fluids.

Authors:  J Rieder
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

View more
  3 in total

Review 1.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

2.  Trimethoprim: prediction of serum concentrations from saliva measurements.

Authors:  I D Watson; M J Stewart
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetic study of the new sulfamethopyrazine-trimethoprim combination (kelfiprim) in renal insufficiency.

Authors:  A Cantaluppi; G Graziani; C Ponticelli; S Grasso; G Meinardi; F Piaia; V Tamassia
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.